Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

By afschroeder • April 17, 2026

Kim YJ, Merle P, Finn RS, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Pinter M, Babajanyan S, Twumasi-Ankrah P, Ghadessi M, Ozgurdal K, Qin S. Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study. ESMO Gastrointest Oncol. 2026 Jan 22;11:100292. doi: 10.1016/j.esmogo.2025.100292. PMID: 41994011; PMCID: PMC13080904.

Tags: Hematology/Oncology, Hepatocellular carcinoma, observational, prospective, Publications, real-world evidence, regorafenib, subgroup analysis

Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care Coordination in Safety-Net Systems

Tupper HI, Doo FX, Lin Y, Flores EJ, Salinas DA, Cummings AL, Ryan GW, Revels SL. Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care[...]

Epigenetic age acceleration measures and chemotoxicity in older adults with early breast cancer

Ji J, Sun CL, Dale W, Kim H, Katheria V, Lee C, Smith C, Sun N, Ding YC, Neuhausen SL, Cohen HJ, Binder A, Sedrak[...]

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial

Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten[...]